Brokers Set Expectations for KROS Q4 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Investment analysts at Wedbush issued their Q4 2025 EPS estimates for shares of Keros Therapeutics in a report issued on Monday, November 4th. Wedbush analyst Y. Zhong anticipates that the company will post earnings of ($1.27) per share for the quarter. Wedbush has a “Strong-Buy” rating on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.90) per share.

KROS has been the subject of a number of other research reports. Cantor Fitzgerald began coverage on shares of Keros Therapeutics in a research report on Thursday, October 24th. They issued an “overweight” rating for the company. Jefferies Financial Group assumed coverage on Keros Therapeutics in a report on Tuesday. They issued a “buy” rating for the company. Scotiabank started coverage on Keros Therapeutics in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 target price on the stock. Bank of America decreased their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Finally, Guggenheim started coverage on Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 price target on the stock. Eleven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $89.11.

Keros Therapeutics Stock Up 6.2 %

Shares of KROS opened at $66.45 on Wednesday. Keros Therapeutics has a twelve month low of $27.31 and a twelve month high of $73.00. The company has a 50 day moving average of $56.87 and a 200-day moving average of $51.89.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The firm had revenue of $0.04 million during the quarter. During the same quarter in the previous year, the company posted ($1.27) earnings per share.

Insiders Place Their Bets

In related news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the transaction, the director now owns 119,522 shares in the company, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 22.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KROS. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Keros Therapeutics by 1.9% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company’s stock valued at $870,000 after acquiring an additional 251 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after purchasing an additional 324 shares during the period. KBC Group NV grew its position in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares in the last quarter. Arizona State Retirement System increased its holdings in shares of Keros Therapeutics by 16.3% during the second quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock worth $369,000 after purchasing an additional 1,130 shares during the period. Finally, American International Group Inc. increased its holdings in shares of Keros Therapeutics by 13.1% during the first quarter. American International Group Inc. now owns 12,653 shares of the company’s stock worth $838,000 after purchasing an additional 1,465 shares during the period. 71.56% of the stock is owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.